MedTrace Logo

Nordic Study in Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma

NCT01458730 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2022-08-04

No results posted yet for this study

Summary

The purpose of the study is to test the efficacy and tolerability of a multiagent chemotherapy treatment regimen without radiotherapy in patients with newly diagnosed lymphoma in the brain.

Conditions

  • Central Nervous System Lymphoma

Interventions

DRUG

Immunochemotherapy

Rituximab, HD-MTX, HD-Ara C, Cyclophosphamide, Iphosphamide, Vincristin, Vindesin, Temozolomide, Depocyte

Sponsors & Collaborators

  • Nordic Cancer Union

    collaborator OTHER

  • Roche Pharma AG

    collaborator INDUSTRY

  • Mundipharma Pte Ltd.

    collaborator INDUSTRY

  • Schering-Plough

    collaborator INDUSTRY

  • University of Aarhus

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2010-10-31
Completion
2022-08-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01458730 on ClinicalTrials.gov